Abstract The nuclear factor κB (NF-κB) is a superfamily of transcription factors. It plays an important role in development
Introduction
The nuclear factor-κB (NF-κB)/REL family of transcription factors is comprised of a RELA/p65,c-REL,RELB, p105/NF-κB1 and p100/NF-κB2 [1] . The members of this family are characterized by the presence of a REL homology domain (RHD) in the N-terminus, which is involved in sequencespecific DNA binding and translocation. The C-terminal regions of these proteins have domains responsible for either transcriptional activation (RELA, c-REL and RELB) or the inhibition of REL protein activity (p105 and p100). The p105 and p100 proteins can be processed by proteolytic cleavage into p50 and p52, respectively. These proteins have Glycine rich regions (GRRs) which are important for this processing. The REL family members are capable of forming different combinations of heterodimers and homodimers, the most common being the p65/p50 heterodimer which is often referred to as the NF-κB complex [2] . Activation of NF-κB signaling pathway leads to the induction of target genes that can inhibit the apoptosis, interaction with cell cycle regulation, cell invasion, contribute to tumorgenesis and Inflammation and metastatic growth as well as chemo resistance and radio resistance [3] . Activation NF-κB in breast cancer is loss of Estrogen Receptor (ER) expression and Human Epidermal Growth Factor Receptor 2 (HER-2) overexpressed via epidermal growth factor receptor (EGFR) and Mitogen Activated Protein Kinase (MAPK) pathway [4] . Indeed, the binding of epidermal growth factor (EGF) to its receptor (EGFR) also ultimately activates NF-κB and most likely contributes to the enhanced activity of this transcription factor in ER negative breast cancer cells [5] . Loss of ER function has been associated with constitutive NFkB activity and hyperactive MAPK, because of constitutive secretion of cytokine and growth factors, which ultimately culminates in aggressive, metastatic, hormone-resistant cancers [6] . Activation of the progesterone receptor can lead to inhibition of NF-κB driven gene expression [7] , reducing its DNA binding and transcriptional activity. HER-2 activates NF-κB through the canonical pathway which surprisingly, involves IKKα [8] . Activation of NF-κB promotes survival of tumor cells. Several gene products that negatively regulate apoptosis in tumor cells are controlled by NF-κB activation [9] . Nottingham Prognostic Index (NPI) is a good prognostic marker as well as survival marker in clinical practice. Estrogen plays an important role in breast cancer initiation and progression. Breast cancer over time acquires different mutations and the proportion of estrogen receptor negative cells in tumor increases. This transformation confers aggressive biological characteristics to breast cancer such as rapid growth, poor differentiation, and poor response to hormone therapy. NF-κB pathway plays important role in this pathway [9] . There are various prognostic markers in breast cancer with variable sensitivity and specificity. We have to find any association NF-κB/p65 expression with clinical parameters such as menopausal status, tumor size, grade, lymph node metastasis, NPI, ER, Progesterone Receptor (PR), HER-2 /neu. This study aims to validate the role of over expression of NF-κB/p65 as a prognostic marker in patients with breast cancer in Indian subcontinent.
Materials and Methods

Patient Selection
The patients were divided into two groups, first group (Group-A) comprised of 57 female patients with primary breast carcinoma previous untreated by chemotherapy, radiotherapy, hormone therapy or a combination of any of the modalities who presented to the Comprehensive Breast Clinic Service & Breast Cancer Research Unit, IPGME&R/SSKM Hospital, Kolkata, West Bengal, India between 2008 and 2011 were included in this research work. Fifty four female patients who were histological and clinically fibro adenoma or benign breast disease treated as control group (Group-B).
Tissue Processing The specimens taken intra-operatively from the resected tumor tissue were washed with phosphate buffered saline (PBS), cut into small pieces and immersed in collagenase at 37°C for 4-6 h. Collagenase incubated tissue was minced and treated with 0.125 % trypsin-EDTA for 10 min. Total protein was extracted by homogenizing cells in ripa : lysis buffer mixture (1:3) at 4°C and measured spectrophotometrically by Lowry's method.
Western Blot Analysis For whole cell lysates, cells were resuspended and homogenized in buffer (100 mM TrisCl, pH 7.4, 300 mM NaCl , 1 % NP-40, and 0.25 % Table 1 Clinicopathological details according to NF-κB/p65 status *Statistically significant 
o d i u m -d e o x y c h o l a t e )
. A l l t h e b u f f e r s w e r e supplemented with protease and phosphatase inhibitor mixtures. For direct Western blot analysis, the cell lysates or the particular fractions were separated by SDS-PAGE, transferred to nitrocellulose membrane (Amersham Hybond-P, GE Healthcare) and probed with specific antibodies, e.g., anti -p65(NF-κB), produced from Santa Cruz thereafter the immunoblots were visualized by chemiluminescence or alkaline phosphatase method. Equal protein loading was confirmed with α-actin antibody (Santa Cruz).
Histology and Immunohistochemistry Breast carcinoma tumors were fixed in 10 % neutral-buffered formalin for 24 h, measured the tumor size, nodal status, grade and embedded in paraffin, and sectioned. For immunohistochemistry, paraffin sections of tumors were deparaffinized and hydrated by successive washes with xylene, 100 % ethanol, and a phosphate buffer [10 mM (pH 7.4) and 0.138 M saline containing 2.7 mM KCl). Antigen retrieval was accomplished with diluted antigen retrieval buffer (DAKO Corp.) Endogenous peroxidase was blocked with 3 % hydrogen peroxide. Subsequently, slides were washed in PBS/KCl, incubated with 10 % normal horse serum followed by the primary antibody (rabbit anti-ER antibody or rabbit anti-PR antibody rabbit anti-c-erbB2; HER-2/neu) and incubated overnight at 4°C. The slides were then incubated with biotinylated secondary antibody for 45 min, followed by ABC reagent and diaminobenzidine. Counterstaining was done with hematoxylin. Sections were dehydrated by washing sequentially with 95 % ethanol, 100 % ethanol, and xylene. Coverslips were mounted on slides using Paramount. Digital images of stained and unstained cells were obtained using an Olympus microscope equipped with a SPOT digital camera.
Statistical Analysis
Categorical variables are expressed as Number of patients and percentage of patients and compared across the two groups using Pearson's Chi Square test for Independence of Attributes. Continuous variables are expressed as Mean±Standard Deviation and compared across the two groups using unpaired t test. The statistical software SPSS version 16 has been used for the analysis. An alpha level of 5 % has been taken, i.e. if any p value is less than 0.05 it has been considered as significant. Table 1 ). The histological grades were measured by Modified BloomRichardson Grading Scheme. Activation of NF-κB was marginally more frequent in high-grade tumors (Grade-III, 86.9 %) compared with low-grade tumors (Grade-I, 37.5 %) and this was statistically significant (p=0.002, Table 1 ). High NF-κB activation was associated with size of the tumor, being more frequently observed in large (≥5 cm) tumors (89.3 %) than small (<2 cm) tumors (42.9 %), and this association was statistical significance (P= 0.012, Table 1 ).No statistically significant association was found between NF-κB expression and lymph node metastasis (P=0.393, Table 1 ). High NF-κB activation was found in patients with a high NPI (NPI≥5.4, 84.6 %) compared with low NPI (<5.4, 44.4 %) and this association was statistically significant (P=0.002, Table 1 ).
Note : NPI=tumor size×0.2+lymph node stage (1=no node, 2=1 to 3 nodes positive, 3=4 or more nodes positive)+grade (1, 2 or 3).
NF-κB activation was more common in ER-negative tumors (81.8 %) than ER-positive tumors (38.5 %) and this difference was statistically significant (P=0.002, Table 2 ). NF-κB activation was more common in PR-negative tumors (82.2 %) than PR-positive tumors (33.3 %) and this difference was statistically significant (P<0.001, Table 2 ). Statistically significant association was found between NF-κB and HER-2/neu expression (P<0.001, Table 2 ). NF-κB activation was more frequent in HER-2/neu positive tumors (96.3 %) compared with HER-2/neu negative tumors (35 %, Table 2 ). Statistically significant association was also found between NF-κB and HER-2/neu positive (Score 3) and HER-2/neu negative (N, Score1, Score2) (P<0.001, Table 2 ).
Discussion
In our study NF-κB/p65 (71.9 %) was activated in case of human invasive ductal breast carcinoma analysed by western blotting, whereas NF-κB was undetectable in control group patients breast tissue. In the present study, activation of NF-κB was significantly correlated with high grade, large tumour size, high NPI value, ER negativity, PR negativity and HER- 5 Shows that NF-κB/p65 was overexpressed in Grade III with compare that Grade II and Grade I by western blot methods Fig. 6 Represents that NF-κB/p65 was overexpressed with HER-2/ neu positive tumor with compare that HER-2/neu negative tumor by western blot methods 2/neu positivity in breast cancer patients. C. Montagut et al. [10] found that there is no significant correlation was found between cytoplasmic or nuclear NF-κB expression and clinical pathological characteristics including tumour size, nodal status, grade, histological type, ER and HER-2/neu but activation of p65 is linked to resistance to neoadjuvant chemotherapy. Yamei Zhou et al. [11] demonstrated that activation of NF-κB identifies a high-risk subset of hormone-dependent breast cancers. Debajit K. Biswas et al. [12] suggested that epidermal growth factor-induced NF-κB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. So NF-κB controls cell-cycle progression by modulating action of cell-cycle regulatory genes. Low level of ER and PR are activated the NF-κB [5] . Harikrishna Nakshatri et al. [13] showed that Constitutive Activation of NF-κB during Progression of Breast Cancer to HormoneIndependent Growth. NF-κB activation is linked to loss of ER expression and activation in IBC and in breast cancer in general. The inverse correlation between NF-κB activation and ER activation is due to EGFR and/or ErbB2 overexpression, resulting in NF-κB activation and ER down regulation [4] . The clinical significance was found between activation of NF-κB transcription factor and overexpression of HER-2/neu oncoprotein [14] (Figs. 1, 2, 3, 4 , 5, and 6).
We found that 89.3 % of tumours more than 5 cm in size activated p65 (Table 1 ) and this was statistically significant (p=0.012). 86.9 % of high grade (Grade III) tumours activated p65 (Table 1 ) and this was statistically significant (p= 0.002). This implies NF-κB is associated with aggressive tumour behaviour such as large tumour size, high grade and poor differentiation. Our study showed that, p65 activated 50 %, 72.7 %, 84.6 %, 66.7 % (Table 1) in breast cancer patients no node, 1-3, 4-9, <9 lymph node metastasis respectively but no significant association was found between lymph node metastasis and p65 activation(p=0.393). NPI is a reliable index to predict overall survival of breast cancer patients over 5 years. Low NPI (NPI<5.4) is associated with good prognosis (about 70 % survival over 5 years) while high NPI (NPI≥5.4) has less than 50 % 5 year survival rate. Our study showed that 84.6 % of tumours expressing p65 had high NPI value (Table 1) & this was statistically significant (p=0.002). Our study also showed that p65 expressing tumours were ER negative and this was statistically significant (Table 2 , p=0.002 and also showed that p65 expressing tumours were PR negative and this was statistically significant (p=0.001). We demonstrated that relation of HER-2/neu with p65 as shown in Table 2 . We found that 96.3 % tumours over expressing HER-2/neu oncoprotein were p65 positive & this association was statistically significant (p<0.001) which was poor prognosis. EC Merkhofer et.al suggested that Activation of NF-κB and PI3K pathways downstream of HER-2, leading to changes in invasion and proliferation of breast cancer cell.
This study also demononstrated that IKKα has a larger role than IKKβ in activation of NF-κB in HER-2 breast cancer cell, including the phosphorylation of the p65 subunit at serine 536 [7] . So activation of NF-κB is the major role of metastasis via IKKα and HER-2/neu activation. Formation of new blood vessels is essential for tumor progression, as the growing tumor mass quickly exceeds the capacity of the native blood supply. Many of the signals that orchestrate angiogenesis are elaborated by tumor-associated macrophages (TAMs), most of which dependent on NF-κB are signaling [15] . NF-κB stimulates proliferation and blocks programmed cell death (apoptosis) in different cell types, including human breast cancers [12, 15, 16] . Various study reported that activated NF-κB is detected in ER-negative human breast cancer cells harboring overexpressed ErbB1 [12, 17, 18] . Activation of NF-κB is the major role in cell proliferation and apoptosis to use an ER-negative and ErbB2-positive expression [19] .
Conclusions
NF-κB over expression implies aggressive tumour biology in breast cancer & it can predict tumours likely to have poor prognosis. Patients with NF-κB positive tumours need to be treated aggressively. We detected a positive correlation between NF-κB and HER-2/neu when studied according to score evaluation. NF-κB expression is directly correlated with ER negative and also associated with higher NPI value which is poor prognostic outcome. In conclusion these data support the oncogenic role of NF-κB in invasive ductal breast carcinoma and highlight its correlation with higher NPI value which is poor outcome for the patients. We also conclude that inhibition NF-κB overexpression may decrease tumour progression in patients and may block breast carcinogenesis, reducing the incidence of breast carcinoma in patients at high risk.
